Abschluss eines nicht exklusiven Rabattvertrages nach§ 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Brivaracetam (ATC-Code: N03AX23) innerhalb des Zeitraumes vom 01.10.2026 bis zum 30.09.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

TENDER DESCRIPTION

For the active substance Brivaracetam (ATC code: N03AX23), AOK Niedersachsen offers non-exclusive discount agreements. For the period until the entry into force of exclusive agreements as a result of a formal procurement procedure in accordance with the rules of Part 4 of the GWB, AOK Niedersachsen offers all interested pharmaceutical companies, without any selection decision, discount agreements. The contract awards are concluded within the framework of an “open-house model” and serve as a bridge between the start of generic competition (expiry of the patent) and the award of exclusive agreements. The agreements offered are not exclusive; agreements with all market participants (pharmaceutical companies) are desired by AOK Niedersachsen. In the open-house model, uniform conditions apply to all participants. Contract content, terms and conditions and access procedures are uniform—individual negotiations are generally not conducted. The contract terms are for a maximum of twenty-four months; the earliest possible start date of the contract is 01.10.2026. All contracts end no later than 30.09.2028, regardless of the date on which the respective contract is concluded. Accession to…

TENDER BRIEF

TENDER DOCUMENTS